Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study

Ibba, Luciano; Gargiulo, Luigi; Alfano, Ângela; Ingurgio, Ruggero Cascio; Narcisi, Alessandra; Costanzo, Antonio; Valenti, Mario

doi:10.1080/09546634.2023.2199108

Cited by 12 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar data have also been observed regarding other IL-17 inhibitors for the treatment of psoriasis [10,11]. In our experience, ixekizumab proved to be equally effective in patients with and without the involvement of difficult-to-treat areas across almost all the endpoints, consistent with available data on IL-17 inhibitors in patients with palmoplantar psoriasis and genital psoriasis [12][13][14]. Current European and Italian guidelines for the treatment of plaque psoriasis do not differentiate between the use of anti-IL-23 and anti-IL-17 agents as first-line therapies.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

Valenti,

Gargiulo,

Ibba

et al. 2024

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safety in both clinical trials and real-world experiences. However, there is a lack of long-term real-world data available for ixekizumab. Methods We conducted a multicenter real-life study to evaluate the effectiveness and safety of ixekizumab in patients with moderate-to-severe plaque psoriasis. Psoriasis Area and Severity Index score (PASI) was collected at baseline and after 1, 2, 3, 4, and 5 years. The occurrence of any adverse events was recorded at each time point. Results We enrolled 1096 patients treated with ixekizumab for at least 1 year. At week 52, the percentages of PASI 90 and PASI 100 were 85.04% and 69.07%, respectively. After 5 years of treatment with ixekizumab, out of 145 patients, a PASI 90 response was achieved by 86.90% of patients, while complete skin clearance was reached by 68.28% of patients. We did not observe any new significant safety findings throughout the study period. Conclusion This study supports the long-term effectiveness and safety of ixekizumab in a real-world setting.

show abstract

Section: Discussionsupporting

confidence: 90%

“…In our experience, ixekizumab proved to be equally effective in patients with and without the involvement of difficult-to-treat areas across almost all the endpoints, consistent with available data on IL-17 inhibitors in patients with palmoplantar psoriasis and genital psoriasis [ 12 – 14 ].…”

Section: Discussionsupporting

confidence: 86%

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

Valenti,

Gargiulo,

Ibba

et al. 2024

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our study highlights that biologics were an effective treatment for patients affected by very severe psoriasis, with 96.15% achieving PASI90 and 88.46% reaching an absolute PASI ≤ 2 after 52 weeks of therapy. The lower PASI90 and PASI100 responses after 16 weeks of treatment are probably ascribed to the high baseline PASI (≥30) and percentage of patients with psoriasis involvement of at least one difficult-to-treat area (70.00%), which are known to have a slower response to biologics [1,24,25]. Interestingly, the line chart for PASI90, PASI100, and PASI ≤ 2 shows an inflection point at week 52 (Figure 1).…”

Section: Discussionmentioning

confidence: 97%

Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study

Fiorillo,

Ibba,

Gargiulo

et al. 2024

JPM

Self Cite

View full text Add to dashboard Cite

Psoriasis can have a significant impact on quality of life and productivity, especially with increased severity. However, there is limited evidence on biologics’ efficacy in highly severe cases compared to moderate-to-severe ones. This study aimed to evaluate the effectiveness and safety of novel biological therapies in very severe psoriasis. We conducted a retrospective analysis on patients ≥ 18 years old affected by very severe psoriasis who had received a biological agent for at least 16 weeks. We used PASI to assess disease severity and effectiveness at weeks 16, 52, 104, and 156. Safety was evaluated by tracking treatment discontinuation rates and adverse events. This study included 29 males and 11 females, with a mean age of 55.80 years (SD 13.82). Cardiometabolic diseases were the most common comorbidities (25.00%). Twenty-eight (70.00%) patients had psoriasis involvement in at least one difficult-to-treat area. All patients completed 16 weeks of treatment. The mean PASI was 31.60 (SD 2.57) at baseline, 3.48 (SD 4.13) at week 16, 0.58 (SD 1.70) at week 52, 0.77 (SD 1.66) at week 104, and 1.29 (SD 2.12) at week 156. PASI90 and 100 were achieved by 52.50% and 30.00% of patients at week 16, by 96.15% and 80.77% at week 52, by 93.33% and 66.67% at week 104, and by 85.71% and 42.86% at week 156. PASIs ≤ 2 were achieved by 50.00% of patients at week 16, 88.46% at week 52, 86.67% at week 104, and 85.71% at week 156. Only two patients discontinued biologics due to complete remission, and mild AEs were reported by four patients. Our findings show that biologics are effective and well tolerated for treating very severe psoriasis, maintaining long-term effectiveness.

show abstract

“…Some studies demonstrated that a reduction in PASI predicted a corresponding reduction in DLQI, which was in line with the findings in this study [ 27 , 28 ]. Psoriasis in hard-to-treat areas such as scalp [ 29 ], genitalia [ 30 ], palms and soles [ 31 ] is usually considered complicated due to the insufficient penetration of the active components of drugs, leading to severe impairment of patients’ quality of life. In fact, such areas certainly had a greater impact on quality of life, even if the lesions were not extensive.…”

Section: Discussionmentioning

confidence: 99%

Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study

Chen

Wei

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

Background Psoriasis critically influences the psychosocial well-being of patients and reduces their quality of life and work efficiency beyond skin symptoms. However, evidence on the association between life quality based on the Dermatology Life Quality Index (DLQI) and psoriasis severity is limited, particularly in China. This study aimed to explore the association between life quality based on the DLQI evaluation and disease severity among psoriasis patients in China. Methods Four thousand two hundred and thirty psoriasis patients were recruited from the Chinese National Clinical Research Center for Skin and Immune Diseases from 2020 to 2021. Information was collected by applying a structured questionnaire and onsite physical examination. Data analysis was performed by using SAS software (version 9.4; SAS Inc., Cary, NC), and statistical significance was set at p < .05. Results Four thousand two hundred and thirty psoriasis patients were predominantly male (64.6%), with a median age of 38.6 years (interquartile range (IQR): 30.0–50.9). The Psoriasis Area and Severity Index (PASI) score for patients with psoriasis was 7.2 (IQR: 3.0–13.5), and 50% of patients with PASI scored over 7. A total of 84.1% of psoriasis patients reported that psoriasis affected their quality of life from mild to severe. The DLQI scores among psoriasis patients were positively correlated with PASI scores ( r = 0.43, p < .01), both in patients of different sex and different age. Logistic regression analysis with the adjustment of potential confounders indicated that patients with higher PASI score also had higher DLQI score, the odds ratio (OR) were 1.69 (95% confidence interval (CI): 1.38–2.08) for patients with PASI score 3–7, 2.61 (95% CI: 2.10–3.25) for patients with PASI score 8–11 and 3.36 (95% CI: 2.78–4.07) for patients with PASI score ≥12, compared with patients with PASI score <3, respectively. Conclusions Life quality based on DLQI evaluation positively correlated with disease severity among patients with psoriasis, especially among male patients and those with higher body mass index. Therefore, we recommend that clinicians treat the DLQI as an important indicator during patient treatment.

show abstract

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study

Cited by 12 publications

References 12 publications

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)

Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study

Life quality among psoriasis patients based on Dermatology Life Quality Index evaluation and its association with psoriasis severity in China: a cross-sectional study

Contact Info

Product

Resources

About